Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population [Hematologic Malignancy]
Conclusion
Imatinib mesylate and new TKIs along with allogeneic stem cell transplantation and other factors have contributed to the life expectancy in patients with CML approaching that of the general population today. This will be an important message to convey to patients to understand the impact of a CML diagnosis on their life. In addition, the increasing prevalence of patients with CML will have a great effect on future health care costs as long as continuous TKI treatment is required.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Bower, Bjorkholm, Dickman, Hoglund, Lambert, Andersson Tags: Population and observational studies (SEER, WHI observational, etc.), Epidemiology Hematologic Malignancy Source Type: research
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Epidemiology | Gleevec | Health | Health Management | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Study | Transplants